Article
Clinical Neurology
Michela Ada Noris Ferilli, Laura Papetti, Massimiliano Valeriani
Summary: This paper presents three case histories of pediatric-onset multiple sclerosis patients and highlights the different uses of fingolimod in treatment, including escalation therapy and first-choice therapy. In all three cases, there was no further disease progression and no adverse events recorded approximately 1 year after initiating fingolimod treatment.
NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
S. Grahl, M. Bussas, B. Wiestler, P. Eichinger, C. Gaser, J. Kirschke, C. Zimmer, A. Berthele, B. Hemmer, M. Muehlau
Summary: This study compared the effects of Fingolimod and Natalizumab in treating relapsing-remitting multiple sclerosis, finding that Fingolimod treatment led to more new white matter lesions but lower overall brain atrophy. The results support the notion that Fingolimod has stronger neuroprotective properties compared to Natalizumab.
Review
Medicine, General & Internal
Athina-Maria Aloizou, Vasileios Siokas, Georgia Pateraki, Ioannis Liampas, Christos Bakirtzis, Zisis Tsouris, George Lazopoulos, Daniela Calina, Anca Oana Docea, Aristidis Tsatsakis, Dimitrios P. Bogdanos, Efthimios Dardiotis
Summary: Numerous studies have explored the potential of using multiple sclerosis disease-modifying drugs in the setting of ischemic stroke, yielding mostly positive results in animal studies. However, concerns on safety and other issues need to be addressed before implementing these drugs in clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Dawn W. Langdon, Davorka Tomic, Iris-Katharina Penner, Pasquale Calabrese, Gary Cutter, Dieter A. Haering, Frank Dahlke, Ludwig Kappos
Summary: The study found that lower cognitive baseline scores correlated with higher disease burden, longer disease duration, and older age in patients with multiple sclerosis. Fingolimod treatment significantly improved cognitive processing speed and attention, regardless of baseline cognitive status.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Zaki Al-Yafeai, Alexander Carvajal-Gonzalez, Hamzah Abduljabar, Muhammed Arvas, Shaan Patel, Neev Patel
Summary: This study comprehensively evaluated the cardiovascular complications of the newly FDA-approved anti-multiple sclerosis (MS) modifying therapies. CD20 and CD25 inhibitors were significantly associated with cardiovascular adverse events, while S1PR agonists showed fewer cardiac complications. These findings are important for personalized prescribing of MS agents based on the patient's cardiovascular profile.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Sekhar Surapaneni, Usha Yerramilli, April Bai, Deepak Dalvie, Jennifer Brooks, Xiaomin Wang, Julie Selkirk, Yingzhuo Grace Yan, Peijin Zhang, Richard Hargreaves, Gondi Kumar, Maria Palmisano, Jonathan Q. Tran
Summary: Absorption, metabolism, and excretion of ozanimod in humans were characterized, and the enzymes involved in complex metabolism were elucidated. Disproportionate metabolites were identified, and the activity of these metabolites was determined.
DRUG METABOLISM AND DISPOSITION
(2021)
Letter
Clinical Neurology
Fernando X. Cuascut, Samir Alkabie, George J. Hutton
Summary: Fingolimod is an oral medication commonly used to treat multiple sclerosis by sequestering certain subsets of lymphocytes. However, post-discontinuation may lead to opportunistic infections like cryptococcal meningitis and IRIS. Surveillance and risk mitigation strategies are recommended.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Haenni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Oezguer Yaldizli
Summary: In a real-world setting, dimethyl fumarate and fingolimod demonstrate comparable effectiveness in reducing relapses and disability worsening in patients with RRMS. Findings from this study suggest that there is no significant difference in efficacy between the two treatment options, regardless of whether patients are treatment-naive or switching from another DMT.
JOURNAL OF NEUROLOGY
(2021)
Article
Cell Biology
Diana Ferraro, Sara De Biasi, Anna Maria Simone, Riccardo Orlandi, Milena Nasi, Francesca Vitetta, Marcello Pinti, Marco Fogliani, Stefano Meletti, Andrea Cossarizza, Patrizia Sola
Summary: The study found that the proportions of Tregs and iNKT cells in the immunoregulatory cell networks changed in patients with Multiple Sclerosis, and FTY treatment may benefit patients by increasing cells with immunomodulatory potential.
Review
Immunology
Andreas Lutterotti, Helen Hayward-Koennecke, Mireia Sospedra, Roland Martin
Summary: Antigen-specific tolerance induction offers personalized treatment for multiple sclerosis by targeting antigens and core pathomechanisms, requiring distinct clinical development approaches. Key aspects include patient selection, outcome measures, demonstrating mechanisms of action, and positioning in the spectrum of MS treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Chiara Zanetta, Massimo Filippi, Lucia Moiola
Summary: Fingolimod has been approved for the treatment of relapsing MS in both adults and children. Real-world data from Italy confirms its effectiveness in pediatric patients with active disease, supporting its use as a therapeutic strategy for pediatric MS.
NEUROLOGICAL SCIENCES
(2021)
Review
Immunology
Zhao Zhao, Chun-Lai Ma, Zhi-Chun Gu, Yue Dong, Yang Lv, Ming-Kang Zhong
Summary: Fingolimod treatment in patients with multiple sclerosis is associated with a significant increase in infection risk, with a 16% higher risk compared to placebo and other active treatments. The risk is especially elevated for lower respiratory infections and herpes virus infections, and does not appear to be dose-dependent.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Emanuela Colombo, Cinthia Farina
Summary: Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that binds to specific G protein-coupled receptors expressed in various organs. Targeting S1P receptors with modulators has shown potential in treating neurological, autoimmune, and inflammatory disorders. These modulators induce lymphopenia and may have immunological effects beyond lymphocyte trafficking inhibition. They can also cross the blood-brain barrier and target CNS resident cells expressing S1P receptors. Understanding the role of S1P signaling in neuroimmunology has important implications for therapeutic approaches in other disease areas.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Neurosciences
G. Sferruzza, F. Clarelli, E. Mascia, L. Ferre, L. Ottoboni, M. Sorosina, S. Santoro, L. Moiola, V. Martinelli, G. Comi, F. Martinelli Boneschi, M. Filippi, P. Provero, Federica Esposito
Summary: The study investigated the gene transcriptional changes induced by FTY in monocytes of multiple sclerosis patients, revealing its major impact on genes associated with cell trafficking and immune cell activation.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Hadas Stiebel-Kalish, Kerstin Rubarth, Karny Shouchane-Blum, Alon Tiosano, Itay Lotan, Mark A. Hellmann, Adi Wilf-Yarkoni, Omer Bialer, Eoin P. Flanagan, Sean J. Pittock, M. Tariq Bhatti, Tanja Schmitz-Huebsch, Paul Friedemann, Susanna Asseyer, John J. Chen
Summary: This study investigates the association between obesity and MOGAD, AQP4-IgG+NMOSD, and MS. The results suggest a significant correlation between obesity and the diagnosis of MOGAD, but not with AQP4-IgG+NMOSD or MS. Further research is needed to validate these findings.
SCIENTIFIC REPORTS
(2022)
Article
Clinical Neurology
Itay Lotan, Thibo Billiet, Annemie Ribbens, Wim Van Hecke, Benny Huang, Ilya Kister, Eyal Lotan
Summary: This study compared global and regional brain volume changes in MOGAD, MS, NMOSD, and healthy controls. The results showed that MOGAD, NMOSD, and MS patients had significantly lower whole brain volume compared to healthy controls. Longitudinal analysis revealed that MOGAD patients had a higher rate of thalamic and hippocampal atrophy compared to MS and NMOSD patients.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
John J. Chen, Eoin P. Flanagan, M. Tariq Bhatti, Nanthaya Tisavipat, Sepideh Jamali, Amy Kunchok, Eric R. Eggenberger, Marie Di Nome, Elias S. Sotirchos, Eleni S. Vasileiou, Amanda D. Henderson, Anthony C. Arnold, Laura Bonelli, Nicolas Seleme, Alvaro J. Mejia-Vergara, Heather E. Moss, Tanyatuth Padungkiatsagul, Hadas Stiebel-Kalish, Itay Lotan, Adi Wilf-Yarkoni, Mark A. Hellmann, Amrita Vuppala, David Hodge, Sean J. Pittock
Summary: This study suggests that eye pain precedes visual loss in the majority of optic neuritis (ON) attacks and early steroid treatment may lead to better outcomes in MOG-IgG associated disease (MOGAD) ON patients, but some patients can recover without steroid treatment. Prospective randomized clinical trials are needed to confirm these findings.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Editorial Material
Clinical Neurology
Michael Levy, Negar Molazadeh, Philippe Antoine Bilodeau, Anastasia Vishnevetsky, Itay Lotan, Rebecca Salky, Monique Anderson, Gabriela Romanow, Jeannette Lechner-Scott, E. Ann Yeh, Gavin Giovannoni
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Susanna Asseyer, Nasrin Asgari, Jeffrey Bennett, Omer Bialer, Yolanda Blanco, Francesca Bosello., Anna Camos-Carreras., Edgar Carnero Contentti., Sara Carta, John Chen, Claudia Chien, Mashina Chomba, Russell C. Dale, Josep Dalmau, Kristina Feldmann, Eoin P. Flanagan, Caroline Froment Tilikete, Carolina Garcia-Alfonso, Joachim Havla, Mark Hellmann, Ho Jin Kim, Philipp Klyscz, Frank Konietschke, Chiara La Morgia, Marco Lana-Peixoto, Maria Isabel Leite, Netta Levin, Michael Levy, Sara Llufriu, Pablo Lopez, Itay Lotan, Alessandra Lugaresi, Romain Marignier, Sara Mariotto, Susan P. Mollan, Cassandra Ocampo, Frederike Cosima Oertel, Maja Olszewska, Jacqueline Palace, Lekha Pandit, Jose Luis Peralta Uribe, Sean Pittock, Sudarshini Ramanathan, Natthapon Rattanathamsakul, Albert Saiz, Sara Samadzadeh, Bernardo Sanchez-Dalmau, Deanna Saylor, Michael Scheel, Tanja Schmitz-Huebsch, Jemal Shifa, Sasitorn Siritho, Pia S. Sperber, Prem S. Subramanian, Alon Tiosano, Adi Vaknin-Dembinsky, Alvaro Jose Mejia Vergara, Adi Wilf-Yarkoni, Luis Alfonso Zarco, Hanna G. Zimmermann, Friedemann Paul, Hadas Stiebel-Kalish
Summary: This is a global study aimed at investigating the effect of early high-dose corticosteroid treatment on optic neuritis. The study will collect various data to evaluate treatment strategies and the accuracy of diagnostic criteria.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Itay Lotan, Gabriela Romanow, Rebecca Salky, Negar Molazadeh, Anastasia Vishnevetsky, Monique Anderson, Phillipe-Antoine Bilodeau, Gary Cutter, Michael Levy
Summary: This study aimed to assess the mortality rate in patients with MOGAD and found a lower mortality rate compared to other neuroinflammatory diseases, similar to the age-adjusted mortality rates of the general population in the United States. Further studies are needed to confirm this observation.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Ophthalmology
John J. Chen, Eoin P. Flanagan, Sean J. Pittock, Nicole Caroline Stern, Nanthaya Tisavipat, M. Tariq Bhatti, Kevin D. Chodnicki, Deena A. Tajfirouz, Sepideh Jamali, Amy Kunchok, Eric R. Eggenberger, Marie A. Di Nome, Elias S. Sotirchos, Eleni S. Vasileiou, Amanda D. Henderson, Anthony C. Arnold, Laura Bonelli, Heather E. Moss, Sylvia Elizabeth Villarreal Navarro, Tanyatuth Padungkiatsagul, Hadas Stiebel-Kalish, Itay Lotan, Adi Wilf-yarkoni, Helen Danesh-Meyer, Stefan Ivanov, Saif Huda, Mirasol Forcadela, David Hodge, Pascale Poullin, Julie Rode, Caroline Papeix, Samir Saheb, Marine Boudot De La Motte, Catherine Vignal, Yael Hacohen, Julie Pique, Elisabeth Maillart, Romain Deschamps, Bertrand Audoin, Romain Marignier
Summary: This study evaluated the effectiveness of plasma exchange (PLEX) for optic neuritis (ON). The results showed that most ON attacks improved with PLEX, and PLEX had better outcomes compared to similar severity cases.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Clinical Neurology
Itay Lotan, John J. Chen, Yael Hacohen, Omar Abdel-Mannan, Sara Mariotto, Saif Huda, Emily Gibbons, Adi Wilf-Yarkoni, Mark A. Hellmann, Hadas Stiebel-Kalish, Sean J. Pittock, Eoin P. Flanagan, Negar Molazadeh, Monique Anderson, Rebecca Salky, Gabriela Romanow, Patrick Schindler, Ankelien Solveig Duchow, Friedemann Paul, Michael Levy
Summary: This retrospective observational study suggests that intravenous immunoglobulins (IVIGs) may be an effective treatment option for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD), leading to significant improvement in patients' disease status.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Neurosciences
Itay Lotan, Shuhei Nishiyama, Amy Wright, Jin Myoung Seok, Michael Levy
Summary: This study assessed the changes in visually evoked potentials (VEP) in MOG-EAE DA rats using a minimally invasive recording device and correlated them with histological findings. The results showed that median VEP latencies were significantly prolonged on days 14, 21, and 28 compared to baseline, with the maximal latency observed on day 21. Histological analysis revealed inflammation and demyelination on days 21 and 28, which correlated with the prolonged VEP latencies. These findings suggest that VEPs can serve as reliable biomarkers for optic nerve involvement in EAE, and the minimally invasive device enables the observation of VEP changes over time in MOG-EAE DA rats. The implications of these findings are important for testing new therapies for CNS demyelinating diseases.
Meeting Abstract
Clinical Neurology
S. Asseyer, K. Feldmann, H. G. Zimmermann, T. Schmitz-Hübsch, O. Bialer, M. Hellmann, A. Tiosano, A. Wilf-Yarkoni, N. Asgari, C. Froment Tilikete, R. Marignier, S. Carta, S. Mariotto, M. I. Leite, J. Palace, E. P. Flanagan, S. Pittock, J. Chen, I. Lotan, M. Levy, S. Ramanathan, R. Dale, F. Paul, H. Stiebel-Kalish
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
C. Chien, V. Cruz Silva, E. Geiter, H. Zimmermann, D. Bichuetti, M. Idagawa, A. Altintas, U. Tanriverdi, S. Siritho, L. Pandit, A. Dcunha, S. Maria Jose, R. Figueiredo, C. Tongco, P. Qian, I. Lotan, V. Khasminsky, M. Hellmann, H. Stiebel-Kalish, D. Rotstein, L. Waxman, D. Ontaneda, K. Nakamura, H. Abboud, M. O. Subei, Y. Mao-Draayer, J. Havla, N. Asgari, P. Skejo, I. Kister, M. Ringelstein, S. Broadley, S. Arnett, B. Marron, A. Jolley, M. Wunderlich, S. Green, L. Cook, M. Yeaman, T. Smith, A. Brandt, J. Wuerfel, F. Paul
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
I. Lotan, J. J. Chen, S. Pittock, E. P. Flanagan, Y. Hacohen, O. Abdel-Mannan, H. Saif, E. Gibbons, A. Wilf-Yarkoni, M. A. Hellmann, H. Stiebel-Kalish, M. Anderson, A. S. Duchow, F. Paul, M. Levy
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
I. Lotan, T. Billiet, A. Ribbens, W. Van Hecke, B. Huang, I. Kister, E. Lotan
MULTIPLE SCLEROSIS JOURNAL
(2022)
Review
Clinical Neurology
Negar Molazadeh, Gauruv Bose, Itay Lotan, Michael Levy
Summary: MOGAD shares similarities with AQP4-IgG + NMOSD in clinical presentations and treatment responses, but has less clear associations with autoimmune diseases and cancers compared to AQP4-IgG + NMOSD, suggesting routine screening for overlapping autoimmunity and neoplasms in MOGAD patients may not be necessary.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL
(2022)
Review
Clinical Neurology
Itay Lotan, Melissa Lydston, Michael Levy
Summary: This study summarizes postmarketing data on neuro-ophthalmological complications following COVID-19 vaccination. The most common adverse event identified was optic neuritis. Despite the risks, the benefits of vaccination outweigh the potential complications.
JOURNAL OF NEURO-OPHTHALMOLOGY
(2022)
